1
|
Guzzinati S, Buja A, Grotto G, Zorzi M, Manfredi M, Bovo E, Del Fiore P, Tropea S, Dall’Olmo L, Rossi CR, Mocellin S, Rugge M. Synchronous and metachronous multiple primary cancers in melanoma survivors: a gender perspective. Front Public Health 2023; 11:1195458. [PMID: 37397750 PMCID: PMC10313207 DOI: 10.3389/fpubh.2023.1195458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2023] [Accepted: 05/30/2023] [Indexed: 07/04/2023] Open
Abstract
Background Long-term survivors of cutaneous malignant melanoma (CMM) risk subsequent malignancies due to both host-related and environmental risk factors. This retrospective population-based study differentially assesses the risk of synchronous and metachronous cancers in a cohort of CMM survivors stratified by sex. Methods The cohort study (1999-2018) included 9,726 CMM survivors (M = 4,873, F = 4,853) recorded by the cancer registry of all 5,000,000 residents in the Italian Veneto Region. By excluding subsequent CMM and non-CMM skin cancers, the incidence of synchronous and metachronous malignancies was calculated according to sex and tumor site, standardizing for age and calendar year. The Standardized Incidence Ratio (SIR) was calculated as the ratio between the number of subsequent cancers among CMM survivors and the expected number of malignancies among the regional population. Results Irrespective of the site, the SIR for synchronous cancers increased in both sexes (SIR = 1.90 in males and 1.73 in females). Both sexes also demonstrated an excess risk for synchronous kidney/urinary tract malignancies (SIR = 6.99 in males and 12.11 in females), and women had an increased risk of synchronous breast cancer (SIR = 1.69). CMM male survivors featured a higher risk of metachronous thyroid (SIR = 3.51, 95% CI [1.87, 6.01]), and prostate (SIR = 1.35, 95% CI [1.12, 1.61]) malignancies. Among females, metachronous cancers featured higher SIR values than expected: kidney/urinary tract (SIR = 2.27, 95% CI [1.29, 3.68]), non-Hodgkin's lymphoma (SIR = 2.06, 95% CI [1.24, 3.21]), and breast (SIR = 1.46, 95% CI [1.22, 1.74]). Females had an overall increased risk of metachronous cancers in the first 5 years after CMM diagnosis (SIR = 1.54 at 6-11 months and 1.37 at 1-5 years). Conclusion Among CMM survivors, the risk of metachronous non-skin cancers is higher than in the general population and differs significantly by sex. These results encourage sex-tailored interventions for metachronous secondary cancer prevention.
Collapse
Affiliation(s)
| | - Alessandra Buja
- Department of Cardiac, Thoracic and Vascular Sciences, and Public Health, University of Padua, Padua, Italy
| | - Giulia Grotto
- Department of Cardiac, Thoracic and Vascular Sciences, and Public Health, University of Padua, Padua, Italy
| | - Manuel Zorzi
- Veneto Tumor Registry, Azienda Zero, Padua, Italy
| | - Mariagiovanna Manfredi
- Department of Cardiac, Thoracic and Vascular Sciences, and Public Health, University of Padua, Padua, Italy
| | | | - Paolo Del Fiore
- Soft-Tissue, Peritoneum, and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Saveria Tropea
- Soft-Tissue, Peritoneum, and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
| | - Luigi Dall’Olmo
- Soft-Tissue, Peritoneum, and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
- Department of Surgery, Oncology and Gastroenterology - DISCOG, University of Padua, Padua, Italy
| | - Carlo R. Rossi
- Department of Surgery, Oncology and Gastroenterology - DISCOG, University of Padua, Padua, Italy
| | - Simone Mocellin
- Soft-Tissue, Peritoneum, and Melanoma Surgical Oncology Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy
- Department of Surgery, Oncology and Gastroenterology - DISCOG, University of Padua, Padua, Italy
| | - Massimo Rugge
- Veneto Tumor Registry, Azienda Zero, Padua, Italy
- Department of Medicine - DIMED, Pathology and Cytopathology Unit, University of Padua, Padua, Italy
| |
Collapse
|
2
|
Antoñanzas J, Morello-Vicente A, Garnacho-Saucedo GM, Redondo P, Aguado-Gil L, Salido-Vallejo R. Risk of Second Primary Malignancies in Melanoma Survivors: A Population-Based Study. Cancers (Basel) 2023; 15:cancers15113056. [PMID: 37297018 DOI: 10.3390/cancers15113056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2023] [Revised: 06/01/2023] [Accepted: 06/01/2023] [Indexed: 06/12/2023] Open
Abstract
(1) Introduction: The association between melanoma (MM) and the occurrence of second primary neoplasms (SPNs) has been extensively studied, with reported incidence rates ranging from 1.5% to 20%. This study aims to evaluate the occurrence of SPNs in patients with a history of primary MM and to describe the factors that make the risk higher in our population. (2) Material and Methods: We conducted a prospective cohort study and calculated the incidence rates and relative risks (RR) for the development of different SPNs in 529 MM survivors from 1 January 2005 to 1 August 2021. Survival and mortality rates were obtained, and the Cox proportional hazards model was used to determine the demographic and MM-related factors that influence the overall risk. (3) Results: Among the 529 patients included, 89 were diagnosed with SPNs (29 prior to MM diagnosis, 11 synchronous, and 49 after MM), resulting in 62 skin tumors and 37 solid organ tumors. The estimated probability of developing SPNs after MM diagnosis was 4.1% at 1 year, 11% at 5 years, and 19% at 10 years. Older age, primary MM location on the face or neck, and histologic subtype of lentigo maligna mm were significantly associated with a higher risk of SPNs. (4) Conclusions: In our population, the risk of developing SPNs was higher in patients with primary MM located on the face and neck and with the histological subtype of lentigo maligna-MM. Age also independently influences the risk. Understanding these hazard factors can aid in the development of MM guidelines with specific follow-up recommendations for individuals with the highest risk.
Collapse
Affiliation(s)
- Javier Antoñanzas
- Dermatology Department, University Clinic of Navarra, 31008 Pamplona, Spain
| | | | | | - Pedro Redondo
- Dermatology Department, University Clinic of Navarra, 31008 Pamplona, Spain
| | - Leyre Aguado-Gil
- Dermatology Department, University Clinic of Navarra, 31008 Pamplona, Spain
| | - Rafael Salido-Vallejo
- Dermatology Department, University Clinic of Navarra, 31008 Pamplona, Spain
- Dermatology Department, Reina Sofía University Hospital, 14004 Cordoba, Spain
| |
Collapse
|
3
|
Banner L, Joffe D, Lee E, Porcu P, Nikbakht N. Incidence of cutaneous melanoma and Merkel cell carcinoma in patients with primary cutaneous B-cell lymphomas: A population study of the SEER registry. Front Med (Lausanne) 2023; 10:1110511. [PMID: 37089593 PMCID: PMC10117954 DOI: 10.3389/fmed.2023.1110511] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2022] [Accepted: 03/14/2023] [Indexed: 04/08/2023] Open
Abstract
IntroductionThe increased incidence of cutaneous melanoma (CM) and Merkel cell carcinoma (MCC) in patients with hematologic malignancies (HM) is well established. While the risk of CM has been assessed in some subtypes of HM including cutaneous T-cell lymphoma, the incidence in patients with primary cutaneous B-cell lymphoma (PCBCL) has not been interrogated.MethodsHere we evaluated the standardized incidence ratio (SIR) of CM and MCC in 5,179 PCBCL patients compared to approximately 1.5 billion individuals in the general population using the Surveillance, Epidemiology and End Results (SEER) database. Among patients with PCBCL, we identified subgroups that were at increased risk for CM or MCC as a second primary cancer.ResultsWe found 36 cases of CM in the PCBCL cohort (SIR, 1.35; 95% CI, 0.94–1.86), among which SIR was significantly elevated for non-Hispanic White patients compared to the general population (SIR, 1.48; 95% CI, 1.03–2.06). Males had a significantly increased risk of developing CM after a diagnosis of PCBCL (SIR, 1.60; 95% CI, 1.10–2.26). We found that males in the age group of 50–59 were at increased risk for CM development (SIR, 3.02; 95% CI, 1.11–6.58). Males were at increased risk of CM 1–5 years after PCBCL diagnosis (SIR, 2.06; 95% CI, 1.18–3.34). Patients were at greater risk of developing MCC within 1 year of diagnosis of PCBCL (SIR, 23.60; 95% CI, 2.86–85.27), particularly in patients who were over the age of 80 (SIR, 46.50; 95% CI, 5.63–167.96). Males aged 60–69 with PCBCL, subtype marginal zone, were also at increased risk for MCC (SIR, 42.71; 95% CI, 1.08–237.99).ConclusionThere is an increased incidence of CM in White, middle-aged males within 5 years of diagnosis of PCBCL and an increased risk of MCC in elderly patients within 1 year of PCBCL diagnosis. These data suggest that certain subgroups of patients with PCBCL may require more rigid surveillance for CM and MCC.
Collapse
Affiliation(s)
- Lauren Banner
- Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA, United States
| | - Daniel Joffe
- Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA, United States
| | - Emily Lee
- Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA, United States
| | - Pierluigi Porcu
- Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation, Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, United States
| | - Neda Nikbakht
- Department of Dermatology and Cutaneous Biology, Thomas Jefferson University, Philadelphia, PA, United States
- *Correspondence: Neda Nikbakht,
| |
Collapse
|
4
|
PD-L1, CD4+, and CD8+ Tumor-Infiltrating Lymphocytes (TILs) Expression Profiles in Melanoma Tumor Microenvironment Cells. J Pers Med 2023; 13:jpm13020221. [PMID: 36836455 PMCID: PMC9965691 DOI: 10.3390/jpm13020221] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Revised: 01/21/2023] [Accepted: 01/25/2023] [Indexed: 02/01/2023] Open
Abstract
(1) Background: Because melanoma is an aggressive tumor with an unfavorable prognosis, we aimed to characterize the PD-L1 expression in melanomas in association with T cell infiltrates because PD-1/PD-L1 blockade represents the target in treating melanoma strategy. (2) Methods: The immunohistochemical manual quantitative methods of PD-L1, CD4, and CD8 TILs were performed in melanoma tumor microenvironment cells. (3) Results: Most of the PD-L1 positive, expressing tumors, have a moderate score of CD4+ TILs and CD8+TILs (5-50% of tumor area) in tumoral melanoma environment cells. The PD-L1 expression in TILs was correlated with different degrees of lymphocytic infiltration described by the Clark system (X2 = 8.383, p = 0.020). PD-L1 expression was observed often in melanoma cases, with more than 2-4 mm of Breslow tumor thickness being the associated parameters (X2 = 9.933, p = 0.014). (4) Conclusions: PD-L1 expression represents a predictive biomarker with very good accuracy for discriminating the presence or absence of malign tumoral melanoma cells. PD-L1 expression was an independent predictor of good prognosis in patients with melanomas.
Collapse
|
5
|
Castel M, Cotten C, Deschamps-Huvier A, Commin MH, Marguet F, Jardin F, Duval-Modeste AB, Joly P. [Primary central nervous system lymphoma following immunotherapy for metastatic melanoma]. Ann Dermatol Venereol 2019; 146:634-639. [PMID: 31122751 DOI: 10.1016/j.annder.2019.04.021] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2018] [Revised: 12/06/2018] [Accepted: 04/16/2019] [Indexed: 11/25/2022]
Abstract
BACKGROUND Anti-PD-1 and anti-CTLA-4 monoclonal antibodies are used in melanoma, while anti-PD-1 are also used in Hodgkin's lymphoma. Primary central nervous system lymphoma is a rare form of non-Hodgkin's lymphoma with few effective treatments. However, several recent studies have reported multiple cases of non-Hodgkin's lymphoma and primary central nervous system lymphoma treated by anti-PD-1 antibodies with favourable responses. PATIENTS AND METHODS This study focuses on the case of a 59-year-old man with metastatic melanoma treated by immunotherapy (anti-CTLA-4 followed by anti-PD-1). He underwent 28 courses of therapy with pembrolizumab. Treatment was stopped after clinical and radiological remission. The patient presented left hemiparesis and a primary central nervous system lymphoma was diagnosed two months after discontinuation of immunotherapy. He started urgent high-dose methotrexate chemotherapy but without significant results. Despite second-line chemotherapy with R-ICE (rituximab-ifosfamide, carboplatin and etoposide), the patient died. DISCUSSION Several hypotheses may be advanced regarding a possible relationship between immunotherapy and the occurrence of this primary central nervous system lymphoma. The lymphoma may have been pre-existing and controlled by immunotherapy, but progressing rapidly after treatment, or it may have been induced by the immunotherapy. However, immunotherapy may have played no role; the relationship between melanoma and lymphoma is well known. CONCLUSION While immunotherapy cannot be unequivocally incriminated in primary central nervous system lymphoma, this case raises many questions about the imputability of immunotherapy in the occurrence of secondary cancers, including lymphomas.
Collapse
Affiliation(s)
- M Castel
- Service de dermatologie, CHU de Rouen, 1, rue de Germont, 76000 Rouen, France.
| | - C Cotten
- Service de dermatologie, CHU de Rouen, 1, rue de Germont, 76000 Rouen, France
| | - A Deschamps-Huvier
- Service de dermatologie, CHU de Rouen, 1, rue de Germont, 76000 Rouen, France
| | - M-H Commin
- Service de dermatologie et service de pharmacovigilance, CHU de Rouen, 1, rue de Germont, 76000 Rouen, France
| | - F Marguet
- Service d'anatomo-pathologie, CHU de Rouen, 1, rue de Germont, 76000 Rouen, France
| | - F Jardin
- Service d'hématologie, centre Henri Becquerel, 1, rue d'Amiens, 76038 Rouen, France
| | - A-B Duval-Modeste
- Service de dermatologie, CHU de Rouen, 1, rue de Germont, 76000 Rouen, France
| | - P Joly
- Service de dermatologie, CHU de Rouen, 1, rue de Germont, 76000 Rouen, France
| |
Collapse
|
6
|
Herr MM, Schonfeld SJ, Dores GM, Withrow DR, Tucker MA, Curtis RE, Morton LM. Mutual Risks of Cutaneous Melanoma and Specific Lymphoid Neoplasms: Second Cancer Occurrence and Survival. J Natl Cancer Inst 2018; 110:1248-1258. [PMID: 29659938 PMCID: PMC6454551 DOI: 10.1093/jnci/djy052] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2017] [Revised: 01/22/2018] [Accepted: 03/02/2018] [Indexed: 01/08/2023] Open
Abstract
Background It is unclear whether the established association between cutaneous melanoma (CM) and lymphoid neoplasms (LNs) differs across LN subtypes. This study quantifies risk for developing CM after specific LNs and, conversely, for developing specific LNs after CM, as well as assessing clinical impact. Methods We identified a cohort of Caucasian adults (age 20-83 years) initially diagnosed with CM or LN, as reported to 17 US population-based cancer registries, 2000-2014. Standardized incidence ratios (SIRs) quantified second cancer risk. We assessed impact of second cancer development on risk of all-cause mortality using Cox regression. Results Among 151 949 one-or-more-year survivors of first primary LN, second primary CM risk was statistically significantly elevated after chronic lymphocytic leukemia/small lymphocytic lymphoma (SIR = 1.96, 95% confidence interval [CI] = 1.74 to 2.21), follicular lymphoma (SIR = 1.32, 95% CI = 1.09 to 1.58), and plasma cell neoplasms (SIR = 1.33, 95% CI = 1.07 to 1.63). Risks for these same subtypes were statistically significantly elevated among 148 336 survivors of first primary CM (SIR = 1.44, 95% CI = 1.25 to 1.66; SIR = 1.47, 95% CI = 1.21 to 1.77; SIR = 1.25, 95% CI = 1.06 to 1.47; respectively). Risk for CM was statistically significantly elevated after diffuse large B-cell lymphoma (SIR = 1.22, 95% CI = 1.02 to 1.45) and Hodgkin lymphoma (SIR = 1.75, 95% CI = 1.33 to 2.26), but the reciprocal relationship was not observed. There were no statistically significant associations between marginal zone lymphoma and CM. Among survivors of most LN subtypes, CM statistically significantly increased risk of death (hazard ratio [HR] range = 1.52, 95% CI = 1.25 to 1.85, to 2.46, 95% CI = 1.45 to 4.16). Among survivors of CM, LN statistically significantly increased risk of death (HR range = 1.75, 95% CI = 1.15 to 2.65, to 6.28, 95% CI = 5.00 to 7.88), with the highest risks observed for the most aggressive LN subtypes. Conclusions Heterogeneous associations between CM and specific LN subtypes provide novel insights into the etiology of these malignancies, with the mutual association between CM and certain LN suggesting shared etiology. Development of second primary CM or LN substantially reduces overall survival.
Collapse
Affiliation(s)
- Megan M Herr
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD
| | - Sara J Schonfeld
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD
| | - Graça M Dores
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD
| | - Diana R Withrow
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD
| | - Margaret A Tucker
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD
| | - Rochelle E Curtis
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD
| | - Lindsay M Morton
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Bethesda, MD
| |
Collapse
|
7
|
Abstract
The Ultraviolet (UV) radiation contained in sunlight is a powerful mutagen and immune suppressant which partly explains why exposure to solar UV is the biggest risk factor for the development of cutaneous tumours. Evidence is building that sunlight may be protective against some internal malignancies. Because patients with these tumours are often vitamin D deficient, this has led some to propose that vitamin D supplementation will be beneficial in the treatment of these cancers. However, the results from already completed trials have been disappointing which has given weight to the argument that there must be something else about sunlight that explains its cancer-protecting properties.
Collapse
Affiliation(s)
- Jacqueline E Marshall
- Cellular Photoimmunology Group, Discipline of Infectious Diseases and Immunology, Sydney Medical School at the Charles Perkins Centre, University of Sydney, Australia.
| | - Scott N Byrne
- Cellular Photoimmunology Group, Discipline of Infectious Diseases and Immunology, Sydney Medical School at the Charles Perkins Centre, University of Sydney, Australia.
| |
Collapse
|
8
|
Lam CJK, Curtis RE, Dores GM, Engels EA, Caporaso NE, Polliack A, Warren JL, Young HA, Levine PH, Elmi AF, Fraumeni JF, Tucker MA, Morton LM. Risk Factors for Melanoma Among Survivors of Non-Hodgkin Lymphoma. J Clin Oncol 2015; 33:3096-104. [PMID: 26240221 DOI: 10.1200/jco.2014.60.2094] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023] Open
Abstract
PURPOSE Previous studies have reported that survivors of non-Hodgkin lymphoma (NHL) have an increased risk of developing cutaneous melanoma; however, risks associated with specific treatments and immune-related risk factors have not been quantified. PATIENTS AND METHODS We evaluated second melanoma risk among 44,870 1-year survivors of first primary NHL diagnosed at age 66 to 83 years from 1992 to 2009 and included in the Surveillance, Epidemiology, and End Results-Medicare database. Information on NHL treatments, autoimmune diseases, and infections was derived from Medicare claims. RESULTS A total of 202 second melanoma cases occurred among survivors of NHL, including 91 after chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and 111 after other NHL subtypes (cumulative incidence by age 85 years: CLL/SLL, 1.37%; other NHL subtypes, 0.78%). Melanoma risk after CLL/SLL was significantly increased among patients who received infused fludarabine-containing chemotherapy with or without rituximab (n=18: hazard ratio [HR], 1.92; 95% CI, 1.09 to 3.40; n=10: HR, 2.92; 95% CI, 1.42 to 6.01, respectively). Significantly elevated risks also were associated with T-cell activating autoimmune diseases diagnosed before CLL/SLL (n=36: HR, 2.27; 95% CI, 1.34 to 3.84) or after CLL/SLL (n=49: HR, 2.92; 95% CI, 1.66 to 5.12). In contrast, among patients with other NHL subtypes, melanoma risk was not associated with specific treatments or with T-cell/B-cell immune conditions. Generally, infections were not associated with melanoma risk, except for urinary tract infections (CLL/SLL), localized scleroderma, pneumonia, and gastrohepatic infections (other NHLs). CONCLUSION Our findings suggest immune perturbation may contribute to the development of melanoma after CLL/SLL. Increased vigilance is warranted among survivors of NHL to maximize opportunities for early detection of melanoma.
Collapse
Affiliation(s)
- Clara J K Lam
- Clara J.K. Lam, Rochelle E. Curtis, Graça M. Dores, Eric A. Engels, Neil E. Caporaso, Joan L. Warren, Joseph F. Fraumeni Jr, Margaret A. Tucker, and Lindsay M. Morton, National Cancer Institute, Rockville, MD; Clara J.K. Lam, Heather A. Young, Paul H. Levine, and Angelo F. Elmi, The George Washington University Milken Institute School of Public Health, Washington, DC; Graça M. Dores, Oklahoma City Veterans Affairs Health Care System, Oklahoma City, Oklahoma; and Aaron Polliack, Hadassah University Hospital, Jerusalem, Israel.
| | - Rochelle E Curtis
- Clara J.K. Lam, Rochelle E. Curtis, Graça M. Dores, Eric A. Engels, Neil E. Caporaso, Joan L. Warren, Joseph F. Fraumeni Jr, Margaret A. Tucker, and Lindsay M. Morton, National Cancer Institute, Rockville, MD; Clara J.K. Lam, Heather A. Young, Paul H. Levine, and Angelo F. Elmi, The George Washington University Milken Institute School of Public Health, Washington, DC; Graça M. Dores, Oklahoma City Veterans Affairs Health Care System, Oklahoma City, Oklahoma; and Aaron Polliack, Hadassah University Hospital, Jerusalem, Israel
| | - Graça M Dores
- Clara J.K. Lam, Rochelle E. Curtis, Graça M. Dores, Eric A. Engels, Neil E. Caporaso, Joan L. Warren, Joseph F. Fraumeni Jr, Margaret A. Tucker, and Lindsay M. Morton, National Cancer Institute, Rockville, MD; Clara J.K. Lam, Heather A. Young, Paul H. Levine, and Angelo F. Elmi, The George Washington University Milken Institute School of Public Health, Washington, DC; Graça M. Dores, Oklahoma City Veterans Affairs Health Care System, Oklahoma City, Oklahoma; and Aaron Polliack, Hadassah University Hospital, Jerusalem, Israel
| | - Eric A Engels
- Clara J.K. Lam, Rochelle E. Curtis, Graça M. Dores, Eric A. Engels, Neil E. Caporaso, Joan L. Warren, Joseph F. Fraumeni Jr, Margaret A. Tucker, and Lindsay M. Morton, National Cancer Institute, Rockville, MD; Clara J.K. Lam, Heather A. Young, Paul H. Levine, and Angelo F. Elmi, The George Washington University Milken Institute School of Public Health, Washington, DC; Graça M. Dores, Oklahoma City Veterans Affairs Health Care System, Oklahoma City, Oklahoma; and Aaron Polliack, Hadassah University Hospital, Jerusalem, Israel
| | - Neil E Caporaso
- Clara J.K. Lam, Rochelle E. Curtis, Graça M. Dores, Eric A. Engels, Neil E. Caporaso, Joan L. Warren, Joseph F. Fraumeni Jr, Margaret A. Tucker, and Lindsay M. Morton, National Cancer Institute, Rockville, MD; Clara J.K. Lam, Heather A. Young, Paul H. Levine, and Angelo F. Elmi, The George Washington University Milken Institute School of Public Health, Washington, DC; Graça M. Dores, Oklahoma City Veterans Affairs Health Care System, Oklahoma City, Oklahoma; and Aaron Polliack, Hadassah University Hospital, Jerusalem, Israel
| | - Aaron Polliack
- Clara J.K. Lam, Rochelle E. Curtis, Graça M. Dores, Eric A. Engels, Neil E. Caporaso, Joan L. Warren, Joseph F. Fraumeni Jr, Margaret A. Tucker, and Lindsay M. Morton, National Cancer Institute, Rockville, MD; Clara J.K. Lam, Heather A. Young, Paul H. Levine, and Angelo F. Elmi, The George Washington University Milken Institute School of Public Health, Washington, DC; Graça M. Dores, Oklahoma City Veterans Affairs Health Care System, Oklahoma City, Oklahoma; and Aaron Polliack, Hadassah University Hospital, Jerusalem, Israel
| | - Joan L Warren
- Clara J.K. Lam, Rochelle E. Curtis, Graça M. Dores, Eric A. Engels, Neil E. Caporaso, Joan L. Warren, Joseph F. Fraumeni Jr, Margaret A. Tucker, and Lindsay M. Morton, National Cancer Institute, Rockville, MD; Clara J.K. Lam, Heather A. Young, Paul H. Levine, and Angelo F. Elmi, The George Washington University Milken Institute School of Public Health, Washington, DC; Graça M. Dores, Oklahoma City Veterans Affairs Health Care System, Oklahoma City, Oklahoma; and Aaron Polliack, Hadassah University Hospital, Jerusalem, Israel
| | - Heather A Young
- Clara J.K. Lam, Rochelle E. Curtis, Graça M. Dores, Eric A. Engels, Neil E. Caporaso, Joan L. Warren, Joseph F. Fraumeni Jr, Margaret A. Tucker, and Lindsay M. Morton, National Cancer Institute, Rockville, MD; Clara J.K. Lam, Heather A. Young, Paul H. Levine, and Angelo F. Elmi, The George Washington University Milken Institute School of Public Health, Washington, DC; Graça M. Dores, Oklahoma City Veterans Affairs Health Care System, Oklahoma City, Oklahoma; and Aaron Polliack, Hadassah University Hospital, Jerusalem, Israel
| | - Paul H Levine
- Clara J.K. Lam, Rochelle E. Curtis, Graça M. Dores, Eric A. Engels, Neil E. Caporaso, Joan L. Warren, Joseph F. Fraumeni Jr, Margaret A. Tucker, and Lindsay M. Morton, National Cancer Institute, Rockville, MD; Clara J.K. Lam, Heather A. Young, Paul H. Levine, and Angelo F. Elmi, The George Washington University Milken Institute School of Public Health, Washington, DC; Graça M. Dores, Oklahoma City Veterans Affairs Health Care System, Oklahoma City, Oklahoma; and Aaron Polliack, Hadassah University Hospital, Jerusalem, Israel
| | - Angelo F Elmi
- Clara J.K. Lam, Rochelle E. Curtis, Graça M. Dores, Eric A. Engels, Neil E. Caporaso, Joan L. Warren, Joseph F. Fraumeni Jr, Margaret A. Tucker, and Lindsay M. Morton, National Cancer Institute, Rockville, MD; Clara J.K. Lam, Heather A. Young, Paul H. Levine, and Angelo F. Elmi, The George Washington University Milken Institute School of Public Health, Washington, DC; Graça M. Dores, Oklahoma City Veterans Affairs Health Care System, Oklahoma City, Oklahoma; and Aaron Polliack, Hadassah University Hospital, Jerusalem, Israel
| | - Joseph F Fraumeni
- Clara J.K. Lam, Rochelle E. Curtis, Graça M. Dores, Eric A. Engels, Neil E. Caporaso, Joan L. Warren, Joseph F. Fraumeni Jr, Margaret A. Tucker, and Lindsay M. Morton, National Cancer Institute, Rockville, MD; Clara J.K. Lam, Heather A. Young, Paul H. Levine, and Angelo F. Elmi, The George Washington University Milken Institute School of Public Health, Washington, DC; Graça M. Dores, Oklahoma City Veterans Affairs Health Care System, Oklahoma City, Oklahoma; and Aaron Polliack, Hadassah University Hospital, Jerusalem, Israel
| | - Margaret A Tucker
- Clara J.K. Lam, Rochelle E. Curtis, Graça M. Dores, Eric A. Engels, Neil E. Caporaso, Joan L. Warren, Joseph F. Fraumeni Jr, Margaret A. Tucker, and Lindsay M. Morton, National Cancer Institute, Rockville, MD; Clara J.K. Lam, Heather A. Young, Paul H. Levine, and Angelo F. Elmi, The George Washington University Milken Institute School of Public Health, Washington, DC; Graça M. Dores, Oklahoma City Veterans Affairs Health Care System, Oklahoma City, Oklahoma; and Aaron Polliack, Hadassah University Hospital, Jerusalem, Israel
| | - Lindsay M Morton
- Clara J.K. Lam, Rochelle E. Curtis, Graça M. Dores, Eric A. Engels, Neil E. Caporaso, Joan L. Warren, Joseph F. Fraumeni Jr, Margaret A. Tucker, and Lindsay M. Morton, National Cancer Institute, Rockville, MD; Clara J.K. Lam, Heather A. Young, Paul H. Levine, and Angelo F. Elmi, The George Washington University Milken Institute School of Public Health, Washington, DC; Graça M. Dores, Oklahoma City Veterans Affairs Health Care System, Oklahoma City, Oklahoma; and Aaron Polliack, Hadassah University Hospital, Jerusalem, Israel
| |
Collapse
|
9
|
Wang J, Pulido JS, O'Neill BP, Johnston PB. Second malignancies in patients with primary central nervous system lymphoma. Neuro Oncol 2014; 17:129-35. [PMID: 24948826 DOI: 10.1093/neuonc/nou105] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND Primary central nervous system lymphoma (PCNSL) is a rare extranodal lymphoma with distinctive biological behaviors. The evolving treatment of PCNSL has greatly improved the outcome for patients with this disease and has stimulated interest in second malignancies (SMs) in patients diagnosed with PCNSL. METHODS The records of 129 cases of PCNSL at Mayo Clinic, diagnosed between January 1, 1988, and November 26, 2012, were reviewed. Data on clinical characteristics, laboratory parameters, treatments, outcomes, and SMs were collected. The mean follow-up time was 44.8 months (range, 0.5-240 months; median, 28.0 months). RESULTS Altogether, 28 cases with 30 (23.26%) SMs were identified. Twenty (15.50%) patients had prior or synchronous SM. Ten (7.76%) patients developed a subsequent primary cancer after PCNSL. The most common sites of prior or synchronous SMs were prostate (4/20), skin (4/20), and gastrointestinal (3/20). The most common site of the subsequent SM was skin (4/10). Two cases were identified with both prior SM and subsequent SM. CONCLUSIONS Second malignancies in cases with PCNSL were not uncommon and occurred in nearly a quarter of our cohort. Nonmelanoma skin cancers were frequently seen. Therefore, screening for SMs should also be considered in long-term follow-up of patients with PCNSL. In addition, the high incidence of subsequent cancer, synchronous cancer, and frequently seen nonmelanoma skin cancers may all indicate an immunosuppressed state in patients with PCNSL.
Collapse
Affiliation(s)
- Jun Wang
- Department of Hematology, First People's Hospital of Changde, Changde, China (J.W.); Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota (J.S.P.); Department of Neurology, Mayo Clinic, Rochester, Minnesota (B.P.O.); Division of Hematology, Mayo Clinic, Rochester, Minnesota (P.B.J.)
| | - Jose S Pulido
- Department of Hematology, First People's Hospital of Changde, Changde, China (J.W.); Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota (J.S.P.); Department of Neurology, Mayo Clinic, Rochester, Minnesota (B.P.O.); Division of Hematology, Mayo Clinic, Rochester, Minnesota (P.B.J.)
| | - Brian Patrick O'Neill
- Department of Hematology, First People's Hospital of Changde, Changde, China (J.W.); Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota (J.S.P.); Department of Neurology, Mayo Clinic, Rochester, Minnesota (B.P.O.); Division of Hematology, Mayo Clinic, Rochester, Minnesota (P.B.J.)
| | - Patrick B Johnston
- Department of Hematology, First People's Hospital of Changde, Changde, China (J.W.); Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota (J.S.P.); Department of Neurology, Mayo Clinic, Rochester, Minnesota (B.P.O.); Division of Hematology, Mayo Clinic, Rochester, Minnesota (P.B.J.)
| |
Collapse
|
10
|
Accuracy of sentinel lymph node dissection for melanoma staging in the presence of a collision tumour with a lymphoproliferative disease. Melanoma Res 2014; 24:371-6. [PMID: 24922190 DOI: 10.1097/cmr.0000000000000098] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Sentinel lymph node dissection (SLND) identifies melanoma patients with metastatic disease who would benefit from radical lymph node dissection (RLND). Rarely, patients with melanoma have an underlying lymphoproliferative disease, and melanoma metastases might develop as collision tumours in the sentinel lymph node (SLN). The aim of this study was to measure the incidence and examine the effect of collision tumours on the accuracy of SLND and on the validity of staging in this setting. Between 1998 and 2012, 750 consecutive SLNDs were performed in melanoma patients using the triple technique (lymphoscintigraphy, gamma probe and blue dye). The validity of SLND in collision tumours was analysed. False negativity was reflected by the disease-free survival. The literature was reviewed on collision tumours in melanoma. Collision tumours of melanoma and chronic lymphocytic leukaemia (CLL) were found in two SLN and in one RLND (0.4%). Subsequent RLNDs of SLND-positive cases were negative for melanoma. The patient with negative SLND developed relapse after 28 months with an inguinal lymph node metastasis of melanoma; RLND showed collision tumours. The literature review identified 12 cases of collision tumours. CLL was associated with increased melanoma incidence and reduced overall survival. This is, to our knowledge, the first assessment of the clinical value of SLND when collision tumours of melanoma and CLL are found. In this small series of three patients with both malignancies present in the same lymph node basin, lymphocytic infiltration of the CLL did not alter radioisotope uptake into the SLN. No false-negative result was observed. Our data suggest the validity of SLND in collision tumours, but given the rarity of the problem, further studies are necessary to confirm this reliability.
Collapse
|
11
|
Tóth V, Hatvani Z, Somlai B, Hársing J, László JF, Kárpáti S. Risk of subsequent primary tumor development in melanoma patients. Pathol Oncol Res 2013; 19:805-10. [PMID: 23681370 DOI: 10.1007/s12253-013-9647-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/10/2013] [Accepted: 04/24/2013] [Indexed: 12/13/2022]
Abstract
Incidence of subsequent malignant tumor development in 740 patients with primary cutaneous melanoma verified between 2006 and 2010 at the Semmelweis University was studied retrospectively and was compared to data of sex and age matched Hungarian population. The follow-up period was 1499 person-years for the whole group from the diagnosis of index melanoma with an average of 2 years. Standardized incidence rate (SIR) was established as the ratio of observed and expected values. The risk of all subsequent malignancies was 15- and 10-fold higher in males (SIR: 15.42) and in females (SIR: 10.55) with melanoma, than in the general population. The increased cancer risk resulted mainly from the significantly higher skin tumor development: SIR values were 160.39 and 92.64 for additional invasive melanoma and 342.28 and 77.04 for subsequent in situ melanoma in males and females, respectively. Non-melanoma skin cancers also notably contributed to the higher risk, the SIR was elevated in both genders to the same extent (males: 17.12, females: 17.55). The risk was also significantly higher for extracutaneous tumor development like chronic lymphocytic leukemia, colon and kidney cancer (both genders), non-Hodgkin's lymphoma, cervical cancer (females), and bladder carcinoma (males). These data underline the importance of patient education and the necessity of frequent medical follow up, including a close-up dermatological screening of melanoma survivors for further malignancies.
Collapse
Affiliation(s)
- Veronika Tóth
- Department of Dermatoloy, Dermatooncology and Venerology, Semmelweis University, 1085 Mária street 41, Budapest, Hungary,
| | | | | | | | | | | |
Collapse
|
12
|
Kurlander DE, Martires KJ, Chen Y, Barnholtz-Sloan JS, Bordeaux JS. Risk of subsequent primary malignancies after dermatofibrosarcoma protuberans diagnosis: a national study. J Am Acad Dermatol 2012; 68:790-6. [PMID: 23261548 DOI: 10.1016/j.jaad.2012.10.040] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/13/2012] [Revised: 10/23/2012] [Accepted: 10/25/2012] [Indexed: 12/22/2022]
Abstract
BACKGROUND Patients frequently live many years after diagnosis of dermatofibrosarcoma protuberans (DFSP). OBJECTIVE We sought to determine the risk of subsequent primary malignancy (SPM) after DFSP diagnosis. METHODS Using the Surveillance, Epidemiology, and End Results database (1973-2008) for 3734 patients with DFSP, we compared the risk of developing 14 SPMs (12 most prevalent cancers in the United States plus other nonepithelial and soft tissue) relative to risk in the general population of same sex, race, and age and year of diagnosis. RESULTS Patients given the diagnosis of DFSP had an overall increased risk of SPM (observed:expected [O:E], 1.20; 95% confidence intervals [CI], 1.04-1.39), with much of the overall increased risk attributable to increased risk of nonepithelial skin cancer (O:E, 9.94; 95% CI, 3.38-22.30). Specifically, female patients with DFSP were at increased risk of other nonepithelial skin cancer (O:E, 14.50; 95% CI, 3.46-38.98), melanoma (O:E, 2.59; 95% CI, 1.02-5.35), and breast cancer (O:E, 1.44; 95% CI, 1.00-2.00). Male patients were not at increased overall risk (O:E, 1.18; 95% CI, 0.96-1.44) of SPM or at increased risk of any specific malignancy (P > .05) adjusted for multiplicity of t tests. LIMITATIONS Surveillance bias may have led to increased rates and earlier detection of primary malignances in patients with DFSP compared with the general population. Individual data that may reveal shared environmental causes of DFSP and SPM were unavailable. CONCLUSIONS Patients with DFSP are at increased risk of a number of SPMs.
Collapse
Affiliation(s)
- David E Kurlander
- Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA
| | | | | | | | | |
Collapse
|
13
|
Fabisiewicz A, Pacholewicz K, Paszkiewicz-Kozik E, Walewski J, Siedlecki JA. Polymorphisms of DNA repair and oxidative stress genes in B-cell lymphoma patients. Biomed Rep 2012; 1:151-155. [PMID: 24648912 DOI: 10.3892/br.2012.31] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2012] [Accepted: 10/10/2012] [Indexed: 11/06/2022] Open
Abstract
The purpose of the study was to investigate the possible association between ERCC2 rs28365048, ERCC5 rs17655, XRCC3 rs861539 and NOS2A rs2297518 polymorphisms with B-cell lymphoma. The study was conducted on 189 patients with CD20+ B-cell lymphoma and 193 controls. The genotype frequencies were compared in the patient and control groups using quantitative polymerase chain reaction, based on allelic discrimination analysis. Our results indicated that variation in NOS2A may be significant in B-cell lymphoma in a population ≥50 years old (OR=2.15; 95% CI, 1.17-3.92; P=0.013). No association was observed between variations in ERCC2, ERCC5, XRCC3 and B-cell lymphoma in the studied population. Our finding of an association between age and NOS2A polymorphisms in lymphoma is unique and requires additional studies. The results concerning ERCC2, ERCC5 and XRCC3 variations add additional data to studies on genetic polymorphisms in the DNA repair pathway.
Collapse
Affiliation(s)
| | | | - Ewa Paszkiewicz-Kozik
- Lymphoid Malignancies, The Maria Sklodowska-Curie Memorial Institute and Oncology Centre, PL-02-781 Warsaw, Poland
| | - Jan Walewski
- Lymphoid Malignancies, The Maria Sklodowska-Curie Memorial Institute and Oncology Centre, PL-02-781 Warsaw, Poland
| | | |
Collapse
|
14
|
Kubica AW, Brewer JD. Melanoma in immunosuppressed patients. Mayo Clin Proc 2012; 87:991-1003. [PMID: 23036673 PMCID: PMC3538393 DOI: 10.1016/j.mayocp.2012.04.018] [Citation(s) in RCA: 80] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/12/2012] [Revised: 04/04/2012] [Accepted: 04/30/2012] [Indexed: 12/17/2022]
Abstract
The immunogenic characteristics of malignant melanoma are intriguing. To date, multiple studies exist regarding the immunogenicity of melanoma. In this article, we summarize data in the literature on the role of immunosuppression in melanoma and discuss several immunocompromised patient populations in detail. A comprehensive PubMed search was conducted with no date limitation. The following search terms were used: melanoma in combination with immunosuppression, immunocompromised, genetics, antigen processing, UV radiation, organ transplantation, organ transplant recipients, lymphoproliferative disease, lymphoma, CLL, NHL, radiation, and HIV/AIDS. Although no formal criteria were used for inclusion of studies, most pertinent studies on the topic were reviewed, with the exception of smaller case reports and case series. The included studies were generally large (≥ 1000 patients in organ transplant recipient studies; ≥ 500 patients in lymphoma studies), with a focus on institutional experiences, or population-based national or international epidemiologic studies. Melanoma-induced immunosuppression, the role of UV radiation in melanoma development, and the epidemiology, clinical course, and prognosis of melanoma in immunocompromised patients are highlighted. Organ transplant recipients, patients with lymphoproliferative disorders, patients with iatrogenic immunosuppression, and patients with human immunodeficiency virus infection/AIDS are also highlighted. Recommendations are proposed for the care and monitoring of immunosuppressed patients with melanoma. With better understanding of the molecular microenvironment and clinical course of melanoma in immunosuppressed patients, novel therapies could be developed and outcomes potentially affected in these patients.
Collapse
Affiliation(s)
| | - Jerry D. Brewer
- Department of Dermatology, Mayo Clinic, Rochester, MN
- Correspondence: Address to Jerry D. Brewer, MD, Department of Dermatology, Mayo Clinic, 200 First St SW, Rochester, MN 55905
| |
Collapse
|
15
|
Current understanding of lifestyle and environmental factors and risk of non-hodgkin lymphoma: an epidemiological update. J Cancer Epidemiol 2012; 2012:978930. [PMID: 23008714 PMCID: PMC3447374 DOI: 10.1155/2012/978930] [Citation(s) in RCA: 45] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2012] [Revised: 07/20/2012] [Accepted: 08/04/2012] [Indexed: 01/07/2023] Open
Abstract
The incidence rates of non-Hodgkin lymphoma (NHL) have steadily increased over the last several decades in the United States, and the temporal trends in incidence can only be partially explained by the HIV epidemic. In 1992, an international workshop sponsored by the United States National Cancer Institute concluded that there was an “emerging epidemic” of NHL and emphasized the need to investigate the factors responsible for the increasing incidence of this disease. Over the past two decades, numerous epidemiological studies have examined the risk factors for NHL, particularly for putative environmental and lifestyle risk factors, and international consortia have been established in order to investigate rare exposures and NHL subtype-specific associations. While few consistent risk factors for NHL aside from immunosuppression and certain infectious agents have emerged, suggestive associations with several lifestyle and environmental factors have been reported in epidemiologic studies. Further, increasing evidence has suggested that the effects of these and other exposures may be limited to or stronger for particular NHL subtypes. This paper examines the progress that has been made over the last twenty years in elucidating the etiology of NHL, with a primary emphasis on lifestyle factors and environmental exposures.
Collapse
|
16
|
Smyth EC, Hsu M, Panageas KS, Chapman PB. Histology and outcomes of newly detected lung lesions in melanoma patients. Ann Oncol 2012; 23:577-582. [PMID: 21821550 DOI: 10.1093/annonc/mdr364] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/06/2023] Open
Abstract
BACKGROUND Melanoma frequently metastasizes to the lung. Improved radiologic techniques may decrease the need for biopsy of such lesions. The aim of this study was to examine factors predictive of a positive biopsy of melanoma. METHODS Using the Memorial Sloan-Kettering Cancer Center melanoma database, all patients with melanoma who had undergone biopsy of a suspicious new lung lesion from 1996 to 2009 were identified. Age, date of diagnosis, histology, and stage were obtained. Chart review was carried out to obtain medical history, smoking status, radiological appearance, and histology of lung lesions biopsied. RESULTS Two hundred and twenty-nine patients were identified; median age was 63 years; 48% were never smokers; 27% had a prior nonmelanoma cancer; 88% of lung nodules were malignant: 69% melanoma, 19% other cancers. Among 113 patients undergoing positron emission tomography (PET), proportions of benign, melanoma, and nonmelanoma 2-[fluorine-18]fluoro-2-deoxy-D-glucose-avid nodules did not differ (P = 0.53). On multivariable analysis, >stage I melanoma, negative smoking history, multiple lung nodules, and no prior nonmelanoma cancer were significantly associated with a melanoma biopsy result rather than other cancer. CONCLUSIONS In this study, 31% of lung lesions were not melanoma. In the subset undergoing PET, this did not differentiate between benign and malignant lesions. Biopsy is mandated in melanoma patients with new lung nodules.
Collapse
Affiliation(s)
| | - M Hsu
- Departments of Epidemiology-Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - K S Panageas
- Departments of Epidemiology-Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA
| | | |
Collapse
|
17
|
Bertrand KA, Chang ET, Abel GA, Zhang SM, Spiegelman D, Qureshi AA, Laden F. Sunlight exposure, vitamin D, and risk of non-Hodgkin lymphoma in the Nurses' Health Study. Cancer Causes Control 2011; 22:1731-41. [PMID: 21987081 DOI: 10.1007/s10552-011-9849-x] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2011] [Accepted: 09/26/2011] [Indexed: 12/14/2022]
Abstract
PURPOSE Case-control studies suggest increased sun exposure reduces non-Hodgkin lymphoma (NHL) risk. Evidence from prospective cohort studies, however, is limited and inconsistent. We evaluated the association between ambient ultraviolet radiation (UV) exposure and NHL in a nationwide cohort of women, the Nurses' Health Study (NHS). METHODS Between 1976 and 2006, we identified 1064 incident NHL cases among 115,482 women in the prospective NHS. Exposures assessed included average annual UV-B flux based on residence at various times during life, vitamin D intake, and predicted plasma 25-hydroxyvitamin D levels. We estimated incidence rate ratios (RRs) and 95% confidence intervals (CIs) for risk of all NHL and histologic subtypes using Cox proportional hazards models. RESULTS NHL risk was increased for women residing in areas of high ambient UV radiation (UV-B flux >113 R-B count × 10(-4)) compared to those with lower exposure (<113), with positive linear trends at all time points. The multivariable-adjusted RR for high UV area at age 15 was 1.21 (95% CI: 1.00, 1.47; p-trend < 0.01). There was no evidence of statistical heterogeneity by subtype, although power was limited for subtype analyses. We observed no association between vitamin D measures and risk of NHL overall or by subtype. CONCLUSIONS Our findings do not support the hypothesis of a protective effect of UV radiation exposure on NHL risk. We found no association between vitamin D and NHL risk.
Collapse
Affiliation(s)
- Kimberly A Bertrand
- Department of Epidemiology, Harvard School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA.
| | | | | | | | | | | | | |
Collapse
|
18
|
Ng AK, LaCasce A, Travis LB. Long-Term Complications of Lymphoma and Its Treatment. J Clin Oncol 2011; 29:1885-92. [DOI: 10.1200/jco.2010.32.8427] [Citation(s) in RCA: 71] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
As a result of therapeutic advances, there is a growing population of survivors of both Hodgkin's lymphoma (HL) and non-Hodgkin's lymphoma (NHL). A thorough understanding of the late effects of cancer and its treatment, including the risk of developing a second malignancy and non-neoplastic complications, most notably cardiac disease, is essential for the proper long-term follow-up care of these patients. For HL survivors cured in the past 5 decades, a large body of literature describes a range of long-term effects, many of which are related to extent of treatment. These studies form the basis for many of the follow-up recommendations developed for HL survivors. As HL therapy continues to evolve, however, with an emphasis toward treatment reduction, in particular for early-stage disease, it will be important to rigorously observe this new generation of patients long term to document and quantify late effects associated with modern treatments. Although data on late effects after NHL therapy have recently emerged, the formulation of structured follow-up plans for this heterogeneous group of survivors is challenging, given the highly variable natural history, treatments, and overall prognosis. However, the chemotherapy and radiation therapy approaches for some types of NHL are similar to that for HL; thus, some of the follow-up guidelines for patients with HL may also be transferrable to selected survivors of NHL. Additional work focused on treatment-related complications after NHL will facilitate the development of follow-up programs, as well as treatment refinements to minimize late effects in patients with various types of NHL.
Collapse
Affiliation(s)
- Andrea K. Ng
- From the Brigham and Women's Hospital; and Dana-Farber Cancer Institute, Boston, MA; and University of Rochester Medical Center, Rochester, NY
| | - Ann LaCasce
- From the Brigham and Women's Hospital; and Dana-Farber Cancer Institute, Boston, MA; and University of Rochester Medical Center, Rochester, NY
| | - Lois B. Travis
- From the Brigham and Women's Hospital; and Dana-Farber Cancer Institute, Boston, MA; and University of Rochester Medical Center, Rochester, NY
| |
Collapse
|
19
|
Pirani M, Marcheselli R, Marcheselli L, Bari A, Federico M, Sacchi S. Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis. Ann Oncol 2011; 22:1845-58. [PMID: 21310758 DOI: 10.1093/annonc/mdq697] [Citation(s) in RCA: 64] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Late side-effects are becoming an important issue in non-Hodgkin's lymphoma (NHL) survivors. We intended to estimate pooled relative risk (RR) of secondary malignant neoplasms (SMNs), to evaluate site-associated RR and the impact of different treatments. DESIGN We carried out an electronic search of Medline and EMBASE seeking articles investigating the risk of SMNs and reporting RR measures. The studies were evaluated for heterogeneity before meta-analysis and for publication bias. Pooled RRs were estimated using fixed- and random-effects models. RESULTS A total of 23 studies met the inclusion criteria. Pooled RRs of SMNs overall and for solid tumors were 1.88 and 1.32, respectively. We found an excess of risk for several specific cancer sites. Radiotherapy alone did not increase the risk for SMNs, while chemotherapy and combined treatments augmented the RR. Regression analyses revealed a positive significant association for all SMNs with total body irradiation, and for solid SMNs with younger age. No publication bias was observed. CONCLUSIONS Our results indicate that NHL patients experience a higher risk for SMNs than the general population and that various treatments have different impact on RR. More information will be necessary to evaluate possible interactions with genetic susceptibility and environmental exposure.
Collapse
Affiliation(s)
- M Pirani
- Department of Oncology and Hematology, University of Modena and Reggio Emilia, Modena, Italy
| | | | | | | | | | | |
Collapse
|
20
|
Hwang CY, Chen YJ, Lin MW, Chen TJ, Chu SY, Chen CC, Lee DD, Chang YT, Wan WJ, Liu HN. Elevated risk of second primary cancer in patients with cutaneous malignant melanoma: A nationwide cohort study in Taiwan. J Dermatol Sci 2010; 60:167-72. [DOI: 10.1016/j.jdermsci.2010.10.004] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/22/2010] [Revised: 09/26/2010] [Accepted: 10/04/2010] [Indexed: 02/08/2023]
|
21
|
Morton LM, Curtis RE, Linet MS, Bluhm EC, Tucker MA, Caporaso N, Ries LAG, Fraumeni JF. Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol 2010; 28:4935-44. [PMID: 20940199 DOI: 10.1200/jco.2010.29.1112] [Citation(s) in RCA: 136] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
PURPOSE Previous studies have shown increased risks of second malignancies after non-Hodgkin's lymphoma (NHL) and chronic lymphocytic leukemia (CLL); however, no earlier investigation has quantified differences in risk of new malignancy by lymphoma subtype. PATIENTS AND METHODS We evaluated second cancer and leukemia risks among 43,145 1-year survivors of CLL/small lymphocytic lymphoma (SLL), diffuse large B-cell lymphoma (DLBCL), or follicular lymphoma (FL) from 11 Surveillance, Epidemiology, and End Results (SEER) population-based registries during 1992 to 2006. RESULTS Among patients without HIV/AIDS-related lymphoma, lung cancer risks were significantly elevated after CLL/SLL and FL but not after DLBCL (standardized incidence ratio [SIR], CLL/SLL = 1.42, FL = 1.28, DLBCL = 1.00; Poisson regression P for difference among subtypes, P(Diff) = .001). A similar pattern was observed for risk of cutaneous melanoma (SIR: CLL/SLL = 1.92, FL = 1.60, DLBCL = 1.06; P(Diff) = .004). Acute nonlymphocytic leukemia risks were significantly elevated after FL and DLBCL, particularly among patients receiving initial chemotherapy, but not after CLL/SLL (SIR: CLL/SLL = 1.13, FL = 5.96, DLBCL = 4.96; P(Diff) < .001). Patients with HIV/AIDS-related lymphoma (n = 932) were predominantly diagnosed with DLBCL and had significantly and substantially elevated risks for second anal cancer (SIR = 120.50) and Kaposi's sarcoma (SIR = 138.90). CONCLUSION Our findings suggest that differing immunologic alterations, treatments (eg, alkylating agent chemotherapy), genetic susceptibilities, and other risk factors (eg, viral infections, tobacco use) among lymphoma subtypes contribute to the patterns of second malignancy risk. Elucidating these patterns may provide etiologic clues to lymphoma as well as to the second malignancies.
Collapse
Affiliation(s)
- Lindsay M Morton
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Department of Health and Human Services, Rockville, MD 20892, USA.
| | | | | | | | | | | | | | | |
Collapse
|
22
|
Synchronous and metachronous malignancies in patients with melanoma: a clinicopathologic study highlighting the role of fine-needle biopsy cytology and potential diagnostic pitfalls. Melanoma Res 2010; 20:203-11. [DOI: 10.1097/cmr.0b013e328335058b] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
23
|
Spanogle JP, Clarke CA, Aroner S, Swetter SM. Risk of second primary malignancies following cutaneous melanoma diagnosis: A population-based study. J Am Acad Dermatol 2010; 62:757-67. [DOI: 10.1016/j.jaad.2009.07.039] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2008] [Revised: 06/25/2009] [Accepted: 07/01/2009] [Indexed: 01/07/2023]
|
24
|
Abstract
The association of cutaneous melanoma and non-Hodgkin lymphoma has been well documented. We identified 117 patients from the Connecticut Tumor Registry between 1973 and 2002 with diagnoses of both melanoma and non-Hodgkin lymphoma. Charts were reviewed based on patients identified with these diagnoses in the Tumor Registry at Yale-New Haven Hospital between 1926 and 2004. Data were analyzed for age at diagnosis, interval between diagnoses, survival, and gender comparisons were also made. Males comprised 62% of the patients. Females diagnosed initially with non-Hodgkin lymphoma developed melanoma after a longer interval than males. All patients diagnosed with non-Hodgkin lymphoma first had decreased survival. No gender-specific survival difference was seen regardless of which malignancy occurred first. The study patients had overall decreased survival than that expected with either melanoma or non-Hodgkin lymphoma alone. The effects of treatment, immunosuppression, viral induction, and genetic mutations may play various roles in the development of these neoplasms. Further research is required to provide insight into the link between melanoma and non-Hodgkin lymphoma.
Collapse
|
25
|
Bradford PT, Freedman DM, Goldstein AM, Tucker MA. Increased risk of second primary cancers after a diagnosis of melanoma. ARCHIVES OF DERMATOLOGY 2010; 146:265-72. [PMID: 20231496 PMCID: PMC3076705 DOI: 10.1001/archdermatol.2010.2] [Citation(s) in RCA: 165] [Impact Index Per Article: 11.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
OBJECTIVE To quantify the risk of subsequent primary cancers among patients with primary cutaneous malignant melanoma. DESIGN Population-based registry study. SETTING We evaluated data from 9 cancer registries of the Surveillance, Epidemiology, and End Results program from 1973-2006. PARTICIPANTS We included 89 515 patients who survived at least 2 months after their initial melanoma diagnosis. RESULTS Of the patients with melanoma, 10 857 (12.1%) developed 1 or more subsequent primary cancers. The overall risk of a subsequent primary cancer increased by 28% (observed to expected [O:E] ratio = 1.28). One quarter of the cancers were subsequent primary melanomas (O:E = 8.61). Women with head and neck melanoma and patients younger than 30 had markedly increased risks (O:E = 13.22 and 13.40, respectively) of developing a subsequent melanoma. Second melanomas were more likely to be thin than were the first of multiple primary melanomas (thickness at diagnosis <1.00 mm, 77.9% vs 70.3%, respectively; P < .001). Melanoma survivors had increased risk of developing several cancers; the most common cancers with elevated risks were breast, prostate, and non-Hodgkin lymphoma (O:E = 1.10, 1.15, and 1.25, respectively). CONCLUSIONS Melanoma survivors have an approximately 9-fold increased risk of developing subsequent melanoma compared with the general population. The risk remains elevated more than 20 years after the initial melanoma diagnosis. This increased risk may be owing to behavioral factors, genetic susceptibility, or medical surveillance. Although the percentage of subsequent primary melanomas thicker than 1 mm is lower than for the first of multiple primary melanomas, it is still substantial. Melanoma survivors should remain under surveillance not only for recurrence but also for future primary melanomas and other cancers.
Collapse
Affiliation(s)
- Porcia T Bradford
- Genetic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, 6120 Executive Boulevard, Rockville, MD 20852, USA.
| | | | | | | |
Collapse
|
26
|
Melanocortin 1 receptor (MC1R), pigmentary characteristics and sun exposure: findings from a case-control study of diffuse large B-cell and follicular lymphoma. Cancer Epidemiol 2010; 34:136-41. [PMID: 20129839 DOI: 10.1016/j.canep.2010.01.005] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2009] [Revised: 01/07/2010] [Accepted: 01/08/2010] [Indexed: 02/03/2023]
Abstract
The relationship between skin cancer and non-Hodgkin lymphoma (NHL) suggests common genetic, host or environmental causes. Ultraviolet radiation (UVR), pigmentary characteristics have been linked with both malignancies, and for skin cancer, the melanocortin 1 receptor (MC1R) which influences pigmentation has also been implicated. This paper reports on the relationship between MC1R, skin, hair and eye colour, time spent outdoors, and diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL). Persons carrying MC1R homozygote variant alleles at R151C, R160W, D294H and D84E were more likely to have fair skin, red hair and to spend less time outdoors than those who did not. The variant allele at V92M was associated with FL (odds ratio (OR)=1.61, 95% confidence interval (CI) 1.08-2.39) and the r:wild type genotype with DLBCL (OR=0.58, 95% CI 0.38-0.89). Interactions between MC1R genotypes and skin colour influenced DLBCL risk; the RR genotype increased risk in individuals with medium or dark skin, based on 5 cases and no controls, but decreased risk among those of fair skin. On the whole, DLBCL and FL risk were not related to genetic variation in MC1R, pigmentation or time spent outdoors.
Collapse
|
27
|
van der Velden HMJ, van Rossum MM, Blokx WAM, Boezeman JBM, Gerritsen MJP. Clinical characteristics of cutaneous melanoma and second primary malignancies in a dutch hospital-based cohort of cutaneous melanoma patients. Dermatol Res Pract 2009; 2009:479183. [PMID: 20585479 PMCID: PMC2879611 DOI: 10.1155/2009/479183] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/19/2008] [Revised: 06/22/2009] [Accepted: 10/18/2009] [Indexed: 11/27/2022] Open
Abstract
The increasing number of living cutaneous melanoma patients and the increased risk of developing a second primary tumour incited us to analyse the clinical characteristics of cutaneous melanoma and define the frequency, site, and type of second primary cancers in cutaneous melanoma patients. We collected data on patients who visited the Department of Dermatology at the Radboud University Nijmegen Medical Centre and were newly diagnosed with cutaneous melanoma or metastasis of melanoma with unknown primary localization between 2002 and 2006. A total of 194 cases were included; eleven patients developed a subsequent melanoma, 24 had at least one basal cell carcinoma, three had at least one squamous cell carcinoma, and 21 patients had a second non-cutaneous primary malignancy. In conclusion, 48 patients developed a subsequent malignancy. As nonmelanoma skin cancer is the most frequent second malignancy, our results subscribe to the necessity of follow-up by a dermatologist.
Collapse
Affiliation(s)
- Haike M. J. van der Velden
- Department of Dermatology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands
| | - Michelle M. van Rossum
- Department of Dermatology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands
| | - Willeke A. M. Blokx
- Department of Pathology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands
| | - Jan B. M. Boezeman
- Department of Dermatology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands
| | - Marie-Jeanne P. Gerritsen
- Department of Dermatology, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands
| |
Collapse
|
28
|
Kanner WA, White KP, Barry CI, Lee AJ, Cousar JB, Wick MR, Patterson JW. Cutaneous T-cell lymphoma occurring with a melanocytic proliferation, masquerading as a nonhealing ulcer with reactive changes. J Cutan Pathol 2009; 38:67-72. [PMID: 20002651 DOI: 10.1111/j.1600-0560.2009.01485.x] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
Two of the most challenging areas in dermatopathology are lymphoproliferative disorders and melanocytic lesions. We present a case of peripheral T-cell lymphoma occurring with an intradermal melanocytic proliferation. A 63-year-old Caucasian man presented with a 12-cm edematous, erythematous to violaceous, scalp ulceration that had enlarged over six months. Previous biopsies showed reactive changes which were concerning for infection. The last biopsies showed small to intermediate sized, angulated cells with clear cytoplasm within the dermis, with extension into the epidermis. These cells stained positive with markers for CD3, CD45RO and CD43, yet showed decreased expression of pan-T-cell markers CD5 and CD7, and absent expression of CD4, CD8, CD56 and CD57 and EBV. Molecular studies showed a clonal T-cell receptor gamma chain gene rearrangement. The diagnosis was peripheral T-cell lymphoma, unspecified. Another biopsy from an indurated area separate from the ulcer showed scattered, enlarged cells embedded in the same lymphocytic infiltrate. No mitotic figures were identified. These cells stained for S100 and Melan-A, in a partly nested arrangement. This was felt to represent a melanocytic nevus. This case likely represents an extraordinary coincidence of two distinctly different neoplasms.
Collapse
Affiliation(s)
- William A Kanner
- Department of Pathology, University of Virginia Health System, Charlottesville, VA 22908-0214, USA.
| | | | | | | | | | | | | |
Collapse
|
29
|
The risk of developing a second, different, cancer among 14 560 survivors of malignant cutaneous melanoma: a study by AIRTUM (the Italian Network of Cancer Registries). Melanoma Res 2008; 18:230-4. [DOI: 10.1097/cmr.0b013e3282fafd0a] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
30
|
Alexander DD, Mink PJ, Adami HO, Chang ET, Cole P, Mandel JS, Trichopoulos D. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer 2007; 120 Suppl 12:1-39. [PMID: 17405121 DOI: 10.1002/ijc.22719] [Citation(s) in RCA: 256] [Impact Index Per Article: 15.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
The non-Hodgkin lymphomas (NHL) are a heterogeneous group of B-cell and T-cell neoplasms that arise primarily in the lymph nodes. NHL incidence rates in the US doubled between about 1970 and 1990, and stabilized during the 1990s. NHL accounts for approximately 3.4% of cancer deaths in the US. Although some of the observed patterns in NHL have been related to HIV/AIDS, these conditions cannot fully explain the magnitude of the changes; neither do changes in classification systems nor improved diagnostic capabilities. Studies of occupational and environmental exposures (e.g., pesticides, solvents) have produced no consistent pattern of significant positive associations. Inverse associations with ultraviolet radiation exposure and alcohol and fish intake, and positive associations with meat and saturated fat intake have been reported in several studies; additional studies are needed to confirm or refute these associations. Family history of NHL or other hematolympho-proliferative cancers and personal history of several autoimmune disorders are associated with increased risk of NHL, but are not likely to account for a large proportion of cases. HIV and other infectious agents, such as human herpesvirus 8 and Epstein-Barr, appear to be associated with differing types of NHL, such as some B-cell lymphomas. Future epidemiologic studies should evaluate associations by NHL type, enhance exposure information collected, and elucidate factors that may identify susceptible (or resistant) subpopulations because of genetic, immunologic or other characteristics. The extent to which the etiology of NHL types may differ is important to resolve in ongoing and future studies.
Collapse
|
31
|
Oliveria SA, Hay JL, Geller AC, Heneghan MK, McCabe MS, Halpern AC. Melanoma survivorship: research opportunities. J Cancer Surviv 2007; 1:87-97. [DOI: 10.1007/s11764-007-0009-y] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/10/2023]
|
32
|
Grant WB. An ecologic study of cancer mortality rates in Spain with respect to indices of solar UVB irradiance and smoking. Int J Cancer 2006; 120:1123-8. [PMID: 17149699 DOI: 10.1002/ijc.22386] [Citation(s) in RCA: 119] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
There is increasing evidence that vitamin D reduces the risk of many types of cancer. Geographic variations in cancer mortality rates in Spain are apparently linked to variations in solar ultraviolet (UV) irradiances and other factors. Cancer mortality rates for 48 continental Spanish provinces for 1978-1992 were used in linear regression analyses with respect to mortality rates for latitude (an index of solar UVB levels), skin cancer (an index of high cumulative UVB irradiance), melanoma (an index related to solar UV irradiance and several other factors) and lung cancer (an index of cumulative effects of smoking). The 9 cancers with mortality rates significantly correlated with latitude for 1 or both sexes were brain, gastric, melanoma, nonmelanoma skin cancer (NMSC), non-Hodgkin's lymphoma (NHL), pancreatic, pleural, rectal and thyroid cancer. Inverse correlations with latitude were found for laryngeal, lung and uterine corpus cancer. The 17 cancers inversely correlated with NMSC are bladder, brain, breast, colon, esophageal, gallbladder, Hodgkin's lymphoma, lung, melanoma, multiple myeloma, NHL, ovarian, pancreatic, pleural, rectal, thyroid and uterine corpus cancer. The 16 correlated with melanoma are bladder, brain, breast, colon, gallbladder, leukemia, lung, multiple myeloma, NHL, ovarian, pancreatic, pleural, prostate, rectal, renal and uterine corpus cancer. The results for lung cancer were in accordance with the literature. These results provide more support for the UVB/vitamin D/cancer hypothesis and indicate a new way to investigate the role of solar UV irradiance on cancer risk. They also provide more evidence that melanoma and NMSC have different etiologies.
Collapse
Affiliation(s)
- William B Grant
- Sunlight, Nutrition, and Health Research Center (SUNARC) 2115 Van Ness Ave., MB 101 San Francisco, CA 94109-2510, USA.
| |
Collapse
|
33
|
Abstract
The etiology of non-Hodgkin lymphoma, as well as its global dramatic rise in incidence during the past decades, remains largely unexplained. However, there is increasing awareness that this group of malignancies may entail not only clinical, morphological and molecular heterogeneity, but also considerable variations in terms of etiologic factors. In this review, epidemiologic patterns are summarized as well as current evidence of associations between various known or suspected risk factors for non-Hodgkin lymphoma overall or for any of its subtypes. Central pathogenetic mechanisms include immunosuppression, especially in relation to T-cell function and loss of control of latent EBV infection, and chronic antigen stimulation. Some degree of familiar aggregation also implies a role for genetic susceptibility. A number of recent investigations of non-Hodgkin lymphoma etiology will hopefully lead to a better understanding of the causes of these malignancies.
Collapse
Affiliation(s)
- Karin Ekström-Smedby
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
| |
Collapse
|
34
|
Tavani A, Bosetti C, Franceschi S, Talamini R, Negri E, La Vecchia C. Occupational exposure to ultraviolet radiation and risk of non-Hodgkin lymphoma. Eur J Cancer Prev 2006; 15:453-7. [PMID: 16912575 DOI: 10.1097/00008469-200610000-00011] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Individuals diagnosed with skin cancer have elevated risk of non-Hodgkin lymphoma, and those with non-Hodgkin lymphoma have excess rates of various types of skin cancers. Sunshine and other sources of ultraviolet radiation are major risk factors for skin cancer, and hence a potential common link between skin cancer and non-Hodgkin lymphoma. We analyzed the relationship between occupational exposure to ultraviolet radiation and the risk for non-Hodgkin lymphoma using data from a case-control study conducted in Northern Italy between 1985 and 1997. Cases were 446 patients with histologically confirmed incident non-Hodgkin lymphoma, and controls were 1295 patients admitted to hospital for acute non-neoplastic, non-immunological conditions. The multivariate odds ratios were computed after allowance for age, sex, area of residence, education and smoking. The odds ratio for patients reporting ever ultraviolet exposure at work was 1.01 (95% confidence interval 0.72-1.43) and 1.03 (95% confidence interval 0.72-1.49) for exposure longer than 10 years. The odds ratio was 1.09 for manual workers and 0.79 for farmers exposed to ultraviolet radiation, compared with those with other occupations not exposed to ultraviolet radiation. Our study found no association between occupational exposure to ultraviolet radiation and the risk of non-Hodgkin lymphoma.
Collapse
|
35
|
Dickinson M, Wotherspoon A, Cunningham D. Sub-clinical dissemination of follicular lymphoma in normal sized lymph nodes may not be detected by radiologic staging: a case of disseminated follicular lymphoma detected in nodal clearance as part of therapy for cutaneous melanoma. Leuk Lymphoma 2006; 47:553-6. [PMID: 16396780 DOI: 10.1080/10428190500305596] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
Abstract
Patients with localized follicular lymphoma are potentially curable; however, the failure rate for local treatment suggests that a proportion of apparently localized disease is being under-staged. We report a case of incidentally diagnosed follicular lymphoma found in association with a stage II malignant melanoma, with immunohistochemical evidence of disseminated lymphoma in radiologically and clinically benign regional lymph nodes. This case provides some evidence to the cause of treatment failure in patients with clinically localized follicular lymphoma, and is a histologically proven example of the association between melanoma and lymphoma.
Collapse
|
36
|
Smedby KE, Lindgren CM, Hjalgrim H, Humphreys K, Schöllkopf C, Chang ET, Roos G, Ryder LP, Falk KI, Palmgren J, Kere J, Melbye M, Glimelius B, Adami HO. Variation in DNA repair genes ERCC2, XRCC1, and XRCC3 and risk of follicular lymphoma. Cancer Epidemiol Biomarkers Prev 2006; 15:258-65. [PMID: 16492913 DOI: 10.1158/1055-9965.epi-05-0583] [Citation(s) in RCA: 49] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
The reasons for the positive association between skin cancer and non-Hodgkin's lymphoma are not known but may be due to common susceptibility involving suboptimal DNA repair. Therefore, we investigated selected polymorphisms and haplotypes in three DNA repair genes, previously associated with skin cancer and DNA repair capacity, in risk of follicular lymphoma, including possible gene interaction with cigarette smoking and sun exposure. We genotyped 19 single nucleotide polymorphisms (SNP) in the ERCC2, XRCC1, and XRCC3 genes in 430 follicular lymphoma patients and 605 controls within a population-based case-control study in Denmark and Sweden. Odds ratios (OR) and 95% confidence intervals (95% CI) were calculated using unconditional logistic regression and haplotype associations were assessed with a global score test. We observed no associations between variation in the ERCC2 and XRCC1 genes and follicular lymphoma risk. In XRCC3, increased risk of follicular lymphoma was suggested for rare homozygotes of three SNPs [Rs3212024: OR, 1.8 (95% CI, 1.1-2.8); Rs3212038: OR, 1.5 (95% CI, 1.0-2.4); Rs3212090: OR, 1.5 (95% CI, 1.0-2.5)]. These results were strengthened in current cigarette smokers. However, evidence of differences in XRCC3 haplotype distributions between follicular lymphoma cases and controls was weak, both overall and in current smokers. We conclude that polymorphic variation in the XRCC3 gene, but not in ERCC2 or XRCC1, may be of importance for susceptibility to follicular lymphoma, perhaps primarily in current smokers. The link between skin cancer and follicular lymphoma is unlikely to be mediated through common variation in the studied DNA repair gene polymorphisms.
Collapse
Affiliation(s)
- Karin Ekström Smedby
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Box 281, SE-171 77 Stockholm, Sweden.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
Arron ST, Kashani-Sabet M. Diagnosis of lymphoma in the draining lymph node basin at the time of in-transit metastasis of cutaneous melanoma. J Am Acad Dermatol 2006; 54:1088-90. [PMID: 16713478 DOI: 10.1016/j.jaad.2005.12.014] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2005] [Revised: 11/16/2005] [Accepted: 12/02/2005] [Indexed: 10/24/2022]
Abstract
The association between cutaneous melanoma and non-Hodgkin's lymphoma (NHL) has been described. Herein we describe two cases in which lymphoma was detected in the draining lymph node basin at the time of the finding of in-transit metastasis of cutaneous melanoma. In both of these cases, sentinel lymph node biopsy at the time of the excision of the primary melanoma showed no evidence of metastatic melanoma or lymphoma. The temporal and spatial correlation of melanoma and NHL in these two cases suggests the possibility of a local failure in immune surveillance.
Collapse
Affiliation(s)
- Sarah Tuttleton Arron
- Department of Dermatology, University of California, San Francisco, California 94143-1706, USA
| | | |
Collapse
|
38
|
Wu YH, Kim GH, Wagner JD, Hood AF, Chuang TY. The association between malignant melanoma and noncutaneous malignancies. Int J Dermatol 2006; 45:529-34. [PMID: 16700785 DOI: 10.1111/j.1365-4632.2005.02640.x] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND Both increases and decreases in the incidence of subsequent malignancies in melanoma patients have been reported. We examined the database of the Indiana University Cancer Center to determine whether there is an association between malignant melanoma and noncutaneous malignancies. OBJECTIVE We searched for evidence of noncutaneous malignancies in a cohort of melanoma patients. METHODS Patients with microscopically confirmed malignant melanoma diagnosed between January 1987 and March 2001 were analyzed. This cohort was investigated for noncutaneous malignancies occurring either before or after the diagnosis of melanoma. The standardized incidence ratios (SIR) were calculated as the ratio of the observed to the expected number of patients with second malignancies, and 95% confidence intervals (95% CI) around the SIR were estimated from the cumulative Poisson distribution. RESULTS A total of 955 patients with melanoma (498 males and 457 females) were documented over the 14-year period. Sixty-nine noncutaneous malignancies were identified in 59 (6.2%) melanoma patients (39 males and 20 females). There was a higher risk of non-Hodgkin's lymphoma (SIR = 1.91; 95% CI, 0.88-3.62) in men and renal cell carcinoma (SIR = 2.41, 95% CI, 0.97-4.97) in men. In female patients, however, there was no higher risk of noncutaneous malignancies. CONCLUSIONS This study did not show a higher risk of prostate cancer, gastrointestinal cancer, leukemia, endometrial cancer, or cancer of the nerve and neuroendocrine systems in melanoma patients. No female patients incurred a higher risk of noncutaneous cancers. The increased risk of non-Hodgkin's lymphoma and renal cell carcinoma in men might be attributed to a mutual carcinogenic exposure, an aberration of cell-mediated immunity, a shared genetic susceptibility, increased medical surveillance among cancer patients, a post-therapy effect after cancer management, or factors not as yet clear. Close monitoring of melanoma patients for signs of second malignancy is warranted.
Collapse
Affiliation(s)
- Yu-Hung Wu
- Department of Dermatology, Mackay Memorial Hospital, Taipei, Taiwan
| | | | | | | | | |
Collapse
|
39
|
Demierre MF, Sondak VK. Cutaneous melanoma: pathogenesis and rationale for chemoprevention. Crit Rev Oncol Hematol 2005; 53:225-39. [PMID: 15718148 DOI: 10.1016/j.critrevonc.2004.11.001] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 11/04/2004] [Indexed: 01/30/2023] Open
Abstract
OBJECTIVE To critically review aspects of melanoma pathogenesis that lend themselves to a chemoprevention strategy. To discuss potential candidate chemoprevention agents with an emphasis on the lipid lowering drugs, the statins, currently, the most promising agents. DATA SOURCES A retrospective review of the literature. STUDY SELECTION Studies included those relevant to melanoma pathogenesis, to the scientific rationale of chemoprevention, and pertinent epidemiologic, pre-clinical, and clinical studies. The referenced study designs and methodologies varied. DATA EXTRACTION AND SYNTHESIS Data were extracted by two reviewers, and the main results are presented in a quantitative descriptive manner. CONCLUSION Melanoma is a preventable disease by altering behavior (sun exposure) among at-risk individuals. There is also considerable evidence to suggest that melanoma development may be prevented or delayed by drugs of sufficiently low toxicity to make clinical trials of chemoprevention feasible and potentially successful. Among potential candidate agents, statins have compelling data for long-term safety and sufficient pre-clinical and clinical evidence for efficacy to justify their evaluation in well-designed trials in high-risk individuals, incorporating intermediate biologic endpoints.
Collapse
Affiliation(s)
- Marie-France Demierre
- Department of Dermatology, Skin Oncology Program, Boston University School of Medicine, Boston Medical Center, 720 Harrison Ave-DOB 801A, Boston, MA 02118, USA.
| | | |
Collapse
|
40
|
Abstract
BACKGROUND The incidence rates of melanoma and non-Hodgkin's lymphoma (NHL) have increased substantially worldwide over the past several decades. It has been hypothesized that ultraviolet light exposure through sunlight may be a common environmental risk factor shared by both skin cancer and NHL. OBJECTIVE The purpose of this study was to better understand the association between skin cancer and NHL and to evaluate its implication in clinical practice. METHODS We reviewed the current literature on the link between the two malignancies and on the role of ultraviolet light in the development of NHL. Publications were selected using a PUBMED search with the terms "non-Hodgkin's lymphoma" and "skin cancer." Epidemiologic studies in English and published after 1995 were the focus. CONCLUSIONS Large population-based studies support an increased risk of subsequent NHL among patients with skin cancers (both melanoma and nonmelanoma skin cancers) and a risk of skin cancer development in patients with NHL, although support for a direct relationship between ultraviolet light and the incidence of NHL is weak and inconsistent. Given their increased risk of developing skin cancers, patients with a history of NHL may benefit from a full-body examination during their visits.
Collapse
Affiliation(s)
- Shasa Hu
- Department of Dermatology and Cutaneous Surgery, University of Miami School of Medicine/Veterans Administration Medical Center, Miami, Florida 33125, USA
| | | | | | | |
Collapse
|
41
|
Smedby KE, Hjalgrim H, Melbye M, Torrång A, Rostgaard K, Munksgaard L, Adami J, Hansen M, Porwit-MacDonald A, Jensen BA, Roos G, Pedersen BB, Sundström C, Glimelius B, Adami HO. Ultraviolet Radiation Exposure and Risk of Malignant Lymphomas. J Natl Cancer Inst 2005; 97:199-209. [PMID: 15687363 DOI: 10.1093/jnci/dji022] [Citation(s) in RCA: 181] [Impact Index Per Article: 9.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND The incidence of malignant lymphomas has been increasing rapidly, but the causes of these malignancies remain poorly understood. One hypothesis holds that exposure to ultraviolet (UV) radiation increases lymphoma risk. We tested this hypothesis in a population-based case-control study in Denmark and Sweden. METHODS A total of 3740 patients diagnosed between October 1, 1999, and August 30, 2002, with incident malignant lymphomas, including non-Hodgkin lymphoma, chronic lymphocytic leukemia, and Hodgkin lymphoma, and 3187 population controls provided detailed information on history of UV exposure and skin cancer and information on other possible risk factors for lymphomas. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated by logistic regression. Statistical tests were two-sided. RESULTS Multivariable-adjusted analyses revealed consistent, statistically significant negative associations between various measures of UV light exposure and risk of non-Hodgkin lymphoma. A high frequency of sun bathing and sunburns at age 20 years and 5-10 years before the interview and sun vacations abroad were associated with 30%-40% reduced risks of non-Hodgkin lymphoma (e.g., for sunbathing four times a week or more at age 20 versus never sunbathing, OR = 0.7, 95% CI = 0.6 to 0.9; for two or more sunburns a year at age 20 versus no sunburns, OR = 0.6, 95% CI = 0.5 to 0.8). These inverse associations increased in strength with increasing levels of exposure (all P(trend)< or =.01). Similar, albeit weaker, associations were observed for Hodgkin lymphoma. There were no clear differences among non-Hodgkin lymphoma subtypes, although associations were stronger for B-cell than for T-cell lymphomas. A history of skin cancer was associated with a doubling in risks of both non-Hodgkin and Hodgkin lymphoma. CONCLUSIONS A history of high UV exposure was associated with reduced risk of non-Hodgkin lymphoma. The positive association between skin cancer and malignant lymphomas is, therefore, unlikely to be mediated by UV exposure.
Collapse
Affiliation(s)
- Karin Ekström Smedby
- Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Box 281, SE-171 77 Stockholm, Sweden.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Lens MB, Newton-Bishop JA. An association between cutaneous melanoma and non-Hodgkin's lymphoma: pooled analysis of published data with a review. Ann Oncol 2005; 16:460-5. [PMID: 15642704 DOI: 10.1093/annonc/mdi080] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Several epidemiological studies have suggested an association between cutaneous melanoma and non-Hodgkin's lymphoma. METHODS We pooled the data from seven cohort studies and calculated the risk of secondary occurrence of cutaneous melanoma after non-Hodgkin's lymphoma, and of non-Hodgkin's lymphoma subsequent to the occurrence of cutaneous melanoma. RESULTS There were 137 612 patients with primary non-Hodgkin's lymphoma and 109 532 patients with primary cutaneous melanoma. We found a statistically significant increased risk of non-Hodgkin's lymphoma among cutaneous melanoma survivors [standardised incidence ratio (SIR) 2.01, 95% confidence interval (CI) 1.79-2.24] and cutaneous melanoma among non-Hodgkin's lymphoma survivors (SIR 1.41, 95% CI 1.26-1.58). CONCLUSION Our study confirmed an association between cutaneous melanoma and non-Hodgkin's lymphoma occurring in the same patient indicative of a need to examine further the role of the common risk factors.
Collapse
Affiliation(s)
- M B Lens
- Genetic Epidemiology Division, Cancer Research UK, St James's University Hospital, Leeds, UK.
| | | |
Collapse
|
43
|
Wejroch MP, Cornillet P, Perceau G, Durlach A, Bernard P. Fréquence des cancers associés dans les lymphomes cutanés. Ann Dermatol Venereol 2004; 131:339-45. [PMID: 15258507 DOI: 10.1016/s0151-9638(04)93612-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
INTRODUCTION The initial staging and follow-up of cutaneous lymphomas is far from being standardized. In this retrospective study, we describe the results of systematic laboratory investigations dedicated to a better definition of the TNM stage for the detection of associated malignancies. PATIENTS AND METHODS This was a retrospective, descriptive, single centre study, including all cases of cutaneous lymphomas seen in the department of dermatology, university hospital of Reims, between 1987 and 2001. Data systematically recorded for each patient included clinical, biological, histological and molecular (cutaneous or circulating T or B clone) findings, imaging (thoracic and abdominal computed tomography scan; or chest X-ray and abdominal ultrasound tomography) and bone marrow histology (for B-cell cutaneous lymphomas only). RESULTS In cutaneous T-cell lymphomas (n=63 including 47 mycosis fongoides), imaging revealed deep lymph nodes in 4 cases, a carcinoma of the kidney in one case, and a benign tumour in 6 cases. A T-cell clone was detected in the skin in 19/33 cases and in peripheral blood in 17/31 cases. In cutaneous B-cell lymphomas (n=23), imaging showed splenomegaly in 2 cases, a B-cell clone was detected in 3/12 cases in the skin, and bone marrow histology was normal in 21/22 cases. Among patients with cutaneous T-cell lymphomas, 14/63 (22 p. 100) had an associated malignancy. In 8/14 cases, the diagnosis of the associated malignancy was made prior to that of the cutaneous T-cell lymphoma. In 4 cases, the interval between the previous malignancy and the diagnosis of lymphoma was <or=2 Years, and in 2 other cases the malignancy was discovered on the occasion of the staging of the T-cell cutaneous lymphoma. CONCLUSION Laboratory investigations in cutaneous lymphomas are necessary to research deep lymph nodes, especially in case of high stage T-cell lymphomas. In exceptional cases they can reveal an associated malignancy, which is usually detected by clinical examination. In cutaneous B-cell lymphoma, bone marrow histology or cytology is generally normal hence may not be justified in low grade or localized cutaneous B-cell lymphomas.
Collapse
Affiliation(s)
- M-P Wejroch
- Service de Dermatologie, CHU Robert Debré, Reims
| | | | | | | | | |
Collapse
|
44
|
Crocetti E, Carli P. Risk of second primary cancers, other than melanoma, in an Italian population-based cohort of cutaneous malignant melanoma patients. Eur J Cancer Prev 2004; 13:33-7. [PMID: 15075786 DOI: 10.1097/00008469-200402000-00006] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
A population-based study has been carried out in central Italy to investigate the risk of further non-melanoma primary cancers in a cohort of cutaneous malignant melanoma (CMM) patients. We considered 1835 invasive CMM cases (93.4% histologically verified) diagnosed between 1985 and 1999 by the Tuscany Cancer Registry, central Italy (1 200000 inhabitants) and actively followed up to the end of 1999 for vital status and for the occurrence of a second primary. Only cases diagnosed after 2 months (metachronous) from CMM diagnosis were considered. During 7758 person-years of observation, 94 cancers were observed (93.6% histologically verified) versus 73.8 expected, corresponding to a standardized incidence ratio (SIR) of 1.27 (95% confidence interval (CI) 1.03-1.56). The risk was similarly increased in both sexes, males SIR=1.31 and females SIR=1.23, and it was statistically significant among subjects younger than 60 years (SIR=1.76) but not among those of 60 years and older (SIR=1.14). Significant increased risks were observed for non-melanoma skin cancers (SIR=3.26) and non-Hodgkin's lymphoma (SIR=2.74). Physicians should be aware of the higher risk for non-Hodgkin's lymphoma and clinical follow-up should include lymph node palpation. However, the risk for extranodal lymphomas should also be kept in mind.
Collapse
Affiliation(s)
- E Crocetti
- UO Epidemiologia Clinica e Descrittiva, CSPO, Via di San Salvi 12, 50135 Florence, Italy.
| | | |
Collapse
|
45
|
Hu S, Ma F, Collado-Mesa F, Kirsner RS. Ultraviolet radiation and incidence of non-Hodgkin's lymphoma among Hispanics in the United States. Cancer Epidemiol Biomarkers Prev 2004; 13:59-64. [PMID: 14744734 DOI: 10.1158/1055-9965.epi-03-0187] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Non-Hodgkin's lymphoma (NHL) is one of the most common cancers among American Hispanics. Several studies suggest that solar UV radiation (UVR) may be an environmental risk contributing to the rise of NHL over the past decades. These studies focused primarily on light-skinned Caucasian populations; it is unknown what role UVR plays in NHL for Hispanics. We described the incidence of NHL in Hispanics from selected states in the United States between 1989 and 2000. To evaluate the role of UVR, we correlated cancer rates with the UV index and latitude of residency. Variations in NHL incidence rates with estimated amount of UVR among whites and blacks from the selected states were also analyzed. We found that NHL occurred less frequently in Hispanics than in whites. Hispanic men had higher incidence of NHL than Hispanic women. Incidence rates of NHL in Hispanics were inversely associated with estimated amount of UVR as an increase in NHL was observed with decreasing UV index (r = -0.7 in men; r = -0.41 in women) or increasing latitude of residency (r = 0.59 in men; r = 0.48 in women). This trend, although it did not reach statistical significance, was also observed in whites and blacks. Our findings do not support previous reports of a positive association between solar radiation and NHL. The inverse relationship between UVR and incidence of NHL is unexplained but presents the need for generation of hypotheses regarding the epidemiology of causal factors for NHL in the United States. Additional studies should be conducted to clarify whether sunlight exposure contributes to the development of NHL.
Collapse
Affiliation(s)
- Shasa Hu
- Department of Dermatology and Cutaneous Surgery, Sylvester Cancer Center, University of Miami School of Medicine, Miami, Florida, USA
| | | | | | | |
Collapse
|
46
|
McKenna DB, Stockton D, Brewster DH, Doherty VR. Evidence for an association between cutaneous malignant melanoma and lymphoid malignancy: a population-based retrospective cohort study in Scotland. Br J Cancer 2003; 88:74-8. [PMID: 12556962 PMCID: PMC2376790 DOI: 10.1038/sj.bjc.6600692] [Citation(s) in RCA: 68] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022] Open
Abstract
We analysed the risk of cutaneous malignant melanoma (CM) occurring in patients following a diagnosis of non-Hodgkin's lymphoma (NHL) or chronic lymphatic leukaemia (CLL), and of NHL or CLL subsequently developing in CM survivors. Cohorts of patients with CM, NHL or CLL (index cancer) diagnosed between 1975 and 1997 were identified from the Scottish national cancer registry and followed through the registry for subsequent CM, NHL or CLL. The standardised incidence ratio (SIR) for each cancer was calculated and overall risk, risk in relation to gender and age at diagnosis of the index cancers and time from diagnosis of the index cancer to the diagnosis of the second malignancy were measured. There were 9385 CM patients, 4016 CLL patients and 13 857 NHL patients identified with an index cancer with 56 195, 14 450 and 44 999 person-years of follow-up, respectively. There was an increased risk of both CLL and NHL following a diagnosis of CM (SIR 2.3 and 1.5, respectively) and of CM following a diagnosis of CLL and NHL (SIR 2.3 and 2.1, respectively). The risk was statistically significantly increased for CLL developing in CM patients and for CM occurring in NHL survivors (P<0.05). This study supports an association between CM, CLL and NHL developing in the same patient. Immunosuppression, exposure to ultraviolet radiation and genetic factors may lead to a host environment that is conducive to the development of these malignancies.
Collapse
Affiliation(s)
- D B McKenna
- Department of Dermatology, Royal Infirmary of Edinburgh, Lauriston Place, Edinburgh EH3 9YW, UK.
| | | | | | | |
Collapse
|
47
|
Tsao H, Kwitkiwski K, Sober AJ. A single-institution case series of patients with cutaneous melanoma and non-Hodgkin's lymphoma. J Am Acad Dermatol 2002; 46:55-61. [PMID: 11756946 DOI: 10.1067/mjd.2001.118353] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
BACKGROUND Over the past two decades, cutaneous melanoma (CM) and non-Hodgkin's lymphoma (NHL) have both experienced unabated increases in incidence. Population-based studies have documented an elevated risk of subsequent NHL among patients with CM and vice versa. METHODS To better characterize the clinical features of patients who have had both malignancies, we retrospectively identified all patients with CM at the Massachusetts General Hospital (MGH) who subsequently had NHL and all NHL patients who later developed CM. RESULTS A total of 2461 CM and 2708 NHL patients were registered at MGH between 1973 and 1998. Out of these groups, 10 CM patients (0.4%) eventually developed NHL and 11 NHL patients (0.4%) subsequently had CM. The mean age at the first CM diagnosis was 56 years, wheras the mean age at the first NHL diagnosis was 67 years. The mean interval to NHL among the CM group was 119 months, whereas the mean interval to CM among the NHL patients was 36 months. All primary CMs were relatively thin (0.95 mm, first diagnosis; 1.07 mm, second diagnosis), and most NHL subtypes were indolent in nature. CONCLUSION The rates of developing a second NHL among CM patients and vice versa are low. Any interactions between CM and NHL may be due to factors such as detection bias, shared environmental ultraviolet carcinogenesis, or possibly, posttreatment effects.
Collapse
Affiliation(s)
- Hensin Tsao
- Department of Dermatology, Massachusetts General Hospital, Boston 02114, USA.
| | | | | |
Collapse
|